Clinical Trial Update: Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sunitinib malate or sorafenib tosylate for kidney cancer post-surgery has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Sorafenib tosylate (sorafenib tosylate)
• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7 | Phase 3 | Status: COMPLETED | Results posted: 2016-12-12